BRPI0910702A2 - polipeptídeos de fator ix modificados e usos dos mesmos - Google Patents

polipeptídeos de fator ix modificados e usos dos mesmos

Info

Publication number
BRPI0910702A2
BRPI0910702A2 BRPI0910702A BRPI0910702A BRPI0910702A2 BR PI0910702 A2 BRPI0910702 A2 BR PI0910702A2 BR PI0910702 A BRPI0910702 A BR PI0910702A BR PI0910702 A BRPI0910702 A BR PI0910702A BR PI0910702 A2 BRPI0910702 A2 BR PI0910702A2
Authority
BR
Brazil
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
BRPI0910702A
Other languages
English (en)
Inventor
Alan Brooks
Chandra Patel
John E Murphy
Kornelia Kirchner
Marian Seto
Ulrich Haupts
Uwe Gritzan
Xiaoqiao Jiang
Original Assignee
Bayer Healthcare Llc
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Bayer Schering Pharma Ag filed Critical Bayer Healthcare Llc
Publication of BRPI0910702A2 publication Critical patent/BRPI0910702A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0910702A 2008-04-16 2009-04-16 polipeptídeos de fator ix modificados e usos dos mesmos BRPI0910702A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17
PCT/US2009/040813 WO2009137254A2 (en) 2008-04-16 2009-04-16 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0910702A2 true BRPI0910702A2 (pt) 2016-07-05

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910702A BRPI0910702A2 (pt) 2008-04-16 2009-04-16 polipeptídeos de fator ix modificados e usos dos mesmos

Country Status (17)

Country Link
EP (1) EP2288622A4 (pt)
JP (1) JP2011517951A (pt)
KR (1) KR20110005862A (pt)
CN (1) CN102083856A (pt)
AU (1) AU2009244633A1 (pt)
BR (1) BRPI0910702A2 (pt)
CA (1) CA2721683A1 (pt)
CO (1) CO6311000A2 (pt)
CR (1) CR11737A (pt)
DO (1) DOP2010000311A (pt)
EC (1) ECSP10010551A (pt)
IL (1) IL208718A0 (pt)
MX (1) MX2010011345A (pt)
RU (1) RU2010146387A (pt)
SG (1) SG189790A1 (pt)
SV (1) SV2010003704A (pt)
WO (1) WO2009137254A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
EP2209487A4 (en) * 2007-10-15 2012-06-20 Univ North Carolina Human factor ix variants with an extended half life
FI3581650T3 (fi) * 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
PT3552619T (pt) 2010-07-09 2025-10-23 Bioverativ Therapeutics Inc Polipéptidos de fator ix e métodos de uso dos mesmos
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
JP5967631B2 (ja) * 2012-04-27 2016-08-10 学校法人日本大学 上皮及び内皮損傷の治療剤
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
CN111372612A (zh) 2017-09-27 2020-07-03 西吉隆医疗股份有限公司 包含活性细胞的方法、组合物和可植入元件
WO2019195055A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
WO2022182869A1 (en) 2021-02-24 2022-09-01 Bluehalo Llc System and method for a digitally beamformed phased array feed
US20260102435A1 (en) 2022-10-11 2026-04-16 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
CN120035657A (zh) 2022-10-11 2025-05-23 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
JP2005501547A (ja) * 2001-09-04 2005-01-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾された第ｉｘ因子
WO2004091487A2 (en) * 2003-04-09 2004-10-28 Wyeth Hemophilia treatment by inhalation of coagulation factors
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
SG189790A1 (en) 2013-05-31
MX2010011345A (es) 2011-02-23
AU2009244633A1 (en) 2009-11-12
JP2011517951A (ja) 2011-06-23
DOP2010000311A (es) 2011-02-28
EP2288622A4 (en) 2012-04-18
CO6311000A2 (es) 2011-08-22
ECSP10010551A (es) 2010-11-30
WO2009137254A3 (en) 2010-01-14
EP2288622A2 (en) 2011-03-02
CA2721683A1 (en) 2009-11-12
WO2009137254A2 (en) 2009-11-12
CR11737A (es) 2011-02-07
SV2010003704A (es) 2011-02-21
CN102083856A (zh) 2011-06-01
IL208718A0 (en) 2010-12-30
KR20110005862A (ko) 2011-01-19
RU2010146387A (ru) 2012-05-27

Similar Documents

Publication Publication Date Title
BR112012002072A2 (pt) polipeptídeos de fator ix modificados e usos dos mesmos
BRPI0911060A2 (pt) polipeptídeos de fator vii que são modificados e usos dos mesmos
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
PT2531206T (pt) Polipéptidos clorotoxina e conjugados e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
IL238669A0 (en) Extended soluble ph20 polypeptides and uses thereof
BRPI0810172A2 (pt) Polipeptídeos de fator vii modificado e seus usos
SMT201600335B (it) Proteine leganti eterodimeri e loro usi
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
DK3663399T3 (da) Modificerede factor IX-polypeptider og anvendelser deraf
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos
BRPI0915142A2 (pt) polipeptídeos, ácido nucleico e usos dos mesmos
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0817312A2 (pt) Polinucleotídeos e polipeptídeos de fago fimru e usos dos mesmo
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
EP2306870A4 (en) BOILER AND BASE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]